KLRS (Kalaris Therapeutics) Ending Cash Position: $43.67 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLRS Kalaris Therapeutics Inc KLRS
12 GF Score
Price $3.93
View Full Analysis

What is Kalaris Therapeutics Ending Cash Position?

Kalaris Therapeutics KLRS -1.02% 12 Ending Cash Position is $43.67 Mil as of Jun. 2026. GuruFocus rates KLRS with a GF Score™ of 12/100.

Kalaris Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 was $43.67 Mil.

Kalaris Therapeutics's quarterly Ending Cash Position declined from Dec. 2025 ($98.55 Mil) to Mar. 2026 ($34.93 Mil) but then increased from Mar. 2026 ($34.93 Mil) to Jun. 2026 ($43.67 Mil).

Kalaris Therapeutics's annual Ending Cash Position declined from Dec. 2023 ($3.17 Mil) to Dec. 2024 ($1.64 Mil) but then increased from Dec. 2024 ($1.64 Mil) to Dec. 2025 ($98.55 Mil).

Kalaris Therapeutics Ending Cash Position Related Terms

Kalaris Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Kalaris Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kalaris Therapeutics Ending Cash Position Chart

Kalaris Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Ending Cash Position
3.06 3.17 1.64 98.55

Kalaris Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.93 42.89 98.55 34.93 43.67
KLRS
12GF Score
Kalaris Therapeutics Inc KLRS
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kalaris Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Kalaris Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1.639+96.914
=98.55

Kalaris Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=34.927+8.746
=43.67

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $43.67 Mil mean?
Kalaris Therapeutics (KLRS) has a Ending Cash Position of $43.67 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Kalaris Therapeutics and its competitors.
Is Kalaris Therapeutics' Ending Cash Position too high?
Kalaris Therapeutics' current Ending Cash Position is $43.67 Mil. Overall, Kalaris Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kalaris Therapeutics' Ending Cash Position compare to VRCA and PTHS?
Kalaris Therapeutics' Ending Cash Position of $43.67 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Kalaris Therapeutics and its competitors. Kalaris Therapeutics's current Ending Cash Position is $43.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kalaris Therapeutics stock overvalued right now?
Kalaris Therapeutics (KLRS) has a current Ending Cash Position of $43.67 Mil. The current Ending Cash Position is $43.67 Mil. Kalaris Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Kalaris Therapeutics (KLRS), the current Ending Cash Position is $43.67 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kalaris Therapeutics Business Description

Address 400 Connell Drive, Suite 5500, Berkeley Heights, NJ, USA, 07922
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
12GF Score

Get the complete analysis for KLRS

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.93
Price